Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oyewole Christopher Durojaiye has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparing Self-Administered Outpatient Parenteral Antimicrobial Therapy (S-OPAT) with Alternative Delivery Models: Risk Factors for Treatment Failure and Complications in a UK Cohort

    by Oyewole Christopher Durojaiye, Charlotte Fiori, Kamille Jaff Maulion, Evangelos I. Kritsotakis

    Self-administered outpatient parenteral antimicrobial therapy (S-OPAT) is an increasingly recognised antimicrobial delivery model, yet comparative evidence on its safety and effectiveness remains limited. We compared clinical outcomes across OPAT delivery models and examined predictors of adverse outcomes in S-OPAT. Adult OPAT episodes at a large UK teaching hospital (January 2023–January 2026) were categorised as S-OPAT, healthcare professional home-administered (H-OPAT), or clinic-based (C-OPAT). Primary outcomes were treatment failure, complications, and 30-day unplanned hospitalisation. Outcome risks were compared using robust multivariable Poisson regression with generalised estimating equations and Bonferroni correction. Among 1064 OPAT episodes, 286 (26.9%) were S-OPAT, and cure/clinical improvement occurred in 912/1064 (85.7%). Treatment failure occurred in 26/286 (9.1%) S-OPAT episodes, with no significantly higher risk than H-OPAT (adjusted relative risk [aRR], 0.72; 98.3% CI, 0.43–1.19) or C-OPAT (aRR, 0.94; CI 0.48–1.84). Rates of unplanned hospitalisation and OPAT-related complications were broadly comparable, except potentially vascular access-related events. Within S-OPAT, older age, higher comorbidity burden, diabetes, peripheral vascular disease, and central venous access were associated with treatment failure. Overall, these findings suggest that S-OPAT can be delivered safely and effectively to appropriately selected patients, while enhanced monitoring may be warranted for older individuals and those with greater comorbidity burden or central venous access devices.

  • Open Access

    Delivery of Outpatient Parenteral Antimicrobial Therapy (OPAT) in an Ever-Changing National Health Service (UK): Benefits, Barriers, and Opportunities

    by Oyewole Christopher Durojaiye, Charlotte Fiori, Katharine Cartwright

    Outpatient parenteral antimicrobial therapy (OPAT) is increasingly used to manage a broad range of infections, enabling patients to receive intravenous antibiotics safely outside inpatient settings. In this review, we examine the current landscape of OPAT practice across the United Kingdom (UK), assessing its clinical, economic, and operational impact. The benefits of OPAT for patients and the National Health Service (NHS), as well as its associated risks, are discussed. Additionally, we explore the challenges hindering its broader implementation within the UK. Finally, we highlight recent innovations and emerging applications of OPAT relevant to the NHS, underscoring key considerations for its future expansion and emphasising the need for a nationally coordinated strategy to realise its full potential.


  • Open Access

    Seroprevalence and Risk Factors for Hepatitis B, HIV, and Syphilis Among Survivors of Sexual Violence in the Eastern Cape Province, South Africa

    by Oladele Vincent Adeniyi, Charity Masilela, Oyewole Christopher Durojaiye

    Understanding the prevalence of hepatitis B (HBV), human immunodeficiency virus (HIV), and syphilis among survivors of sexual violence in South Africa is crucial for guiding targeted healthcare interventions, despite the limited available data. This study aimed to investigate the prevalence of these infections and their associated risk factors in survivors from the Eastern Cape Province, South Africa. This retrospective cross-sectional study reviewed 1957 medical records of survivors of sexual violence who received care at two large healthcare facilities in the Eastern Cape Province of South Africa between January 2019 and December 2020. All survivors were screened for HBV, HIV, and syphilis infections. Logistic regression analysis was used to identify factors associated with HIV and syphilis infections. The overall seroprevalence rates for HBV, syphilis, and HIV were 0.7%, 4.9%, and 17.3%, respectively. Six individuals were co-infected with at least two of these infections. Predictors for HIV infection included age (age < 16: adjusted odds ratio [aOR] 0.05; 95% confidence interval [CI], 0.03–0.08 and ages 16–25: aOR 0.45; 95% CI, 0.34–0.59) and black race (aOR 4.78; 95% CI, 1.09–20.88). Predictors for syphilis infection were age (age < 16: aOR 0.05; 95% CI, 0.02–0.15 and ages 16–25: aOR 0.41; 95% CI, 0.25–0.66) and residing in an urban area (aOR 0.23; 95% CI, 0.10–0.50). Survivors of sexual violence are at increased risk of HBV, HIV, and syphilis. Urgent measures are needed to provide comprehensive screening, treatment, prevention, and education to address this critical public health issue.

  • Open Access

    Effects of the timing of maternal antiretroviral therapy initiation, CD4 count, and HIV viral load on birth outcomes in the Eastern Cape province of South Africa: A secondary data analysis

    by Sisanda Siqithi, Oyewole Christopher Durojaiye, Oladele Vincent Adeniyi

    Background: Antiretroviral therapy (ART) use during pregnancy is essential to prevent vertical transmission of HIV, but it may also increase the risk of adverse birth outcomes. This study investigated the impact of both maternal HIV infection and the timing of ART initiation on birth outcomes in women living with HIV in South Africa.Methods: This secondary data analysis examined the dataset from an earlier cohort study involving 1709 pregnant women living with HIV who delivered their babies at three major maternity centres in the Eastern Cape province of South Africa between September 2015 and May 2018. The associations between adverse birth outcomes (stillbirth, preterm birth, very preterm birth, and low birth weight) and the timing of maternal ART initiation, peripartum CD4 count, and HIV viral load were examined using logistic regression analysis.Results: The observed rates of stillbirth, preterm birth, very preterm birth, and low birth weight were 1.4%, 33.5%, 5.4% and 18.0%, respectively. In the multivariable analysis, low birth weight was associated with ART initiated during the second trimester (adjusted odds ratio [aOR] 1.38; 95% confidence interval [CI], 1.03–1.85), low-level viraemia (21–999 copies/ml) (aOR, 1.62; 95% CI, 1.17–2.22), and high-level viraemia (≥1000 copies/ml) (aOR, 1.66; 95% CI, 1.66–2.38) during the peripartum period. Preterm birth was associated with low-level viraemia (aOR, 1.44; 95% CI, 1.16–1.79) and a CD4 count of less than 200 cells/mm3(aOR, 1.35; 95% CI, 1.01–1.82). Very preterm birth was associated with detectable maternal viraemia.Conclusion: Adverse birth outcomes are common among pregnant women living with HIV, especially those with unsuppressed viraemia. Clinicians and programme managers should prioritise timeous ART initiation and virological suppression in all pregnant women living with HIV.


  • Open Access

    Colistin utilization at a tertiary hospital in South Africa: an opportunity for antimicrobial stewardship practices

    by Gaalebale Prudence Matshediso, Oyewole Christopher Durojaiye, Oladele Vincent Adeniyi

    Introduction. Colistin (polymyxin E) has emerged as a last-resort treatment option for multidrug-resistant infections. Hypothesis/Gap Statement. Studies on the use, safety and efficacy of colistin in South Africa are limited. Aim. This study aims to describe the use of colistin and its clinical outcomes at a tertiary public hospital in South Africa. Methodology. We conducted a retrospective review of adult and paediatric patients who received parenteral colistin between 2015 and 2019. Results. A total of 69 patients (26 adults, 13 children and 30 neonates) were reviewed. Acinetobacter baumannii was the most common causative pathogen isolated (70.1 %). Colistin was predominately used to treat septicaemia (75.4 %). It was primarily administered as definitive therapy (71.0 %) and as monotherapy (56.5 %). It was used in 11.5 % of adults with infections susceptible to other antibiotics. Loading doses of intravenous colistin were administered in only 15 (57.7 %) adult patients. Neurotoxicity and nephrotoxicity occurred in 5.8 % and 43.5 % of patients, respectively. Clinical cure was achieved in 37 (53.6 %) patients. On multivariate logistic regression analysis, adults [adjusted odds ratio (aOR), 25.54; 95 % CI, 2.73–238.65; P < 0.01] and children (aOR, 8.56; 95 % CI, 1.06–69.10; P < 0.05) had higher odds of death than neonates. Conclusion. The study identified significant stewardship opportunities to improve colistin prescription and administration. Achieving optimal patient outcomes necessitates a multidisciplinary approach and vigilant monitoring of colistin use.


  • Evaluation of health-related quality of life in patients receiving outpatient parenteral antimicrobial therapy (OPAT) in a UK setting

    by Oyewole Christopher Durojaiye, Evangelos I. Kritsotakis

    Studies assessing the benefits of outpatient parenteral antimicrobial therapy (OPAT) have paid less attention to patient-centered factors such as patients' experiences and their health-related quality of life (HRQoL). Prospective before-and-after quasi-experimental study enrolled adult patients receiving OPAT at a tertiary hospital in Derbyshire, UK, between October 2022 and October 2023. Consenting patients completed paired EQ-5D-3 L questionnaires before OPAT initiation and upon completion of therapy or 30 days after its commencement (whichever occurred first). Changes and predictors of change in HRQoL indicators and associations with clinical outcomes (treatment failure, adverse events, and 30-day unplanned readmission) were examined. Health state index and visual analogue scale (EQ VAS) scores of 162 enrolled patients were significantly lower than the UK population averages, but the patients experienced significant improvements in both scores and in four EQ-5D dimensions (mobility, self-care, usual activities, and pain/discomfort). Baseline health index and EQ VAS scores were significant independent predictors of positive changes in HRQoL scores. OPAT is associated with improved patient-reported quality of life and facilitates early return to work or school. Nevertheless, it is crucial to closely monitor patients with a lower baseline quality of life to optimize their overall OPAT experience.


  • Open Access

    Persistence of SARS-CoV-2 IgG Antibody Response among South African Adults: A Prospective Cohort Study

    by Oladele Vincent Adeniyi, Oyewole Christopher Durojaiye, Charity Masilela

    This study assesses the durability of severe acute respiratory coronavirus-2 (SARS-CoV-2) anti-nucleocapsid (anti-N) immunoglobulin G (IgG) after infection and examines its association with established risk factors among South African healthcare workers (HCWs). Blood samples were obtained from 390 HCWs with diagnosis of coronavirus disease 2019 (COVID-19) for assay of the SARS-CoV-2 anti-N IgG at two time points (Phase 1 and 2) between November 2020 and February 2021. Out of 390 HCWs with a COVID-19 diagnosis, 267 (68.5%) had detectable SARS-CoV-2 anti-N IgG antibodies at the end of Phase I. These antibodies persisted for 4–5 and 6–7 months in 76.4% and 16.1%, respectively. In the multivariate logistic regression model analysis, Black participants were more likely to sustain SARS-CoV-2 anti-N IgG for 4–5 months. However, participants who were HIV positive were less likely to sustain SARS-CoV-2 anti-N IgG antibodies for 4–5 months. In addition, individuals who were <45 years of age were more likely to sustain SARS-CoV-2 anti-N IgG for 6–7 months. Of the 202 HCWs selected for Phase 2, 116 participants (57.4%) had persistent SARS-CoV-2 anti-N IgG for an extended mean period of 223 days (7.5 months). Findings support the longevity of vaccine responses against SARS-CoV-2 in Black Africans.


  • Open Access

    Persistence of SARS-Cov-2 Igg Antibody Response among South African Adults: A Prospective Cohort Study

    by Oladele Vincent Adeniyi, Oyewole Chris Durojaiye, Charity Masilela

    This study assesses the durability of severe acute respiratory coronavirus-2 (SARS-CoV-2) anti-nucleocapsid (anti-N) immunoglobulin G (IgG) after infection, and examines its association with established risk factors among South African healthcare workers (HCWs). Blood samples were obtained from 390 HCWs with diagnosis of coronavirus disease 2019 (COVID-19) for assay of the SARS-CoV-2 anti-N IgG at two time points (Phase 1 & 2) between November 2020 and February 2021. Out of 390 HCWs with COVID-19 diagnosis, 267 (68.5%) had detectable SARS-CoV-2 anti-N IgG antibodies at the end of phase I. These antibodies persisted for 4-5 and 6-7 months in 76.4% and 16.1%, respectively. In the multivariate logistic regression model analysis, black participants were more likely to sustain SARS-CoV-2 anti-N IgG for 4-5 months. However, participants who were HIV positive were less likely to sustain SARS-CoV-2 anti-N IgG antibodies for 4-5 months. In addition, individuals who were <45 years of age were more likely to sustain SARS-CoV-2 anti-N IgG for 6-7 months. Of the 202 HCWs selected for phase 2, 116 participants (57.4%) had persistent SARS-CoV-2 anti-N IgG for an extended mean period of 223 days (7.5 months). Findings support the longevity of vaccine responses against SARS CoV-2 in black Africans.